Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509850 | 0.97 | P2RX4 (0.30) | CYSLTR1P2RX4NR1H2NR1H3 | |
| SCHEMBL14718185 | 0.87 | ADORA2A (0.32) | P2RX4NR1H2NR1H3 | |
| SCHEMBL210445 | 0.82 | ABL1 (0.35) | MTNR1AMTNR1B | |
| SCHEMBL211841 | 0.78 | TRPM8 (0.32) | P2RX4NR1H2NR1H3 | |
| SCHEMBL213278 | 0.77 | CRHR1 (0.32) | NR1H2NR1H3 | |
| SCHEMBL210413 | 0.73 | P2RX4 (0.33) | P2RX4 | |
| SCHEMBL213402 | 0.72 | P2RX4 (0.35) | P2RX4 | |
| SCHEMBL212126 | 0.72 | P2RX4 (0.32) | P2RX4 | |
| SCHEMBL212808 | 0.72 | P2RX4 (0.33) | P2RX4 | |
| SCHEMBL211522 | 0.72 | P2RX4 (0.33) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CYSLTR1 1542/4885MTNR1A 93/4885MTNR1B 83/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CYSLTR1 1542/4885MTNR1A 93/4885MTNR1B 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.